HRS-5817
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 21, 2025
A Trial of HRS-5817 in Obese Participants
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Atridia Pty Ltd.
New P1 trial • Genetic Disorders • Obesity
November 18, 2025
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
(clinicaltrials.gov)
- P1 | N=92 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | N=44 ➔ 92 | Trial completion date: Apr 2026 ➔ Apr 2027 | Trial primary completion date: Apr 2026 ➔ Apr 2027
Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity
April 18, 2025
A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
(clinicaltrials.gov)
- P1 | N=44 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
New P1 trial • Genetic Disorders • Obesity
1 to 3
Of
3
Go to page
1